Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
CRSP
CRISPR Therapeutics
$70.62
Login to see CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Outperform the market
Chart
$55.89 (+26.36%)
$55.14 (+28.07%)
$38.77 (+82.15%)
$48.04 (+47.00%)
CRSP has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
CRSP overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
CRSP Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRSP Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayCRSP Earnings
The TTM reflects 12-month period, providing review of CRSP financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
VCEL
33.16
-1.87%
IBRX
2.50
-1.19%
CLDI
1.60
+2.56%
BNTX
106.14
+0.86%
AMGN
295.54
+0.15%
What is CRSP current stock price?
What are CRSP stock strengths?
What risks are associated with CRSP stock?
When is CRSP next earnings report?
What is CRSP market cap and volume?
What is CRSP's current Stock IQ?
Should I buy CRSP stock right now?
Is CRSP a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRSP?
What does a 'Strong Sell' rating mean for CRSP?
What factors influence CRSP's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
CRSP
CRISPR Therapeutics
Current Price
$70.62
Stock Insights
Strengths
Earnings are forecast to grow
Outperform the market
Linked to CRSP
VCEL
33.16
-1.87%
IBRX
2.50
-1.19%
CLDI
1.60
+2.56%
BNTX
106.14
+0.86%
AMGN
295.54
+0.15%
Login to unlock CRISPR Therapeutics (CRSP) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$55.89 (+26.36%)
$55.14 (+28.07%)
$38.77 (+82.15%)
$48.04 (+47.00%)
CRSP Analysts Opinion
CRSP Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
CRSP Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRSP Street view is bullish and have positive views on the near-term outlook
CRSP has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
Average key support and resistance price levels.
Login to displayCRSP Earnings
The TTM data reflects the most recent 12-month period, providing overview of CRSP financial performance.
CRSP Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
CRSP Latest Analysis
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences. CAMBRIDGE Mass. Oct. 06 2025 (GLOBE NEWSWIRE) -- Editas Medicine Inc. (NASDAQ:) a pioneering gene editing company focused on developing transformative medicines for serious diseases today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress to be held October 7-10
Mon Oct 6, 2025
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know. CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day reflecting a -6.98% change compared to its last close.
Fri Oct 3, 2025
Looking At CRISPR Therapeuticss Recent Unusual Options Activity. High-rolling investors have positioned themselves bearish on CRISPR Therapeutics (NASDAQ:CRSP) and it'.s important for retail traders to take note.\This activity came to our attention today through Benzinga'.s tracking of publicly available options data. The identities of these investors are uncertain but such a significant move in CRSP often signals that someone has privileged information.Today Benzinga'.s options scan
Thu Oct 2, 2025
H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics AG (CRSP) Stock. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23 analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on the companys stock while keeping the price objective at $80.00. As per the firm the current price target does not yet include any contribution from [….]
Wed Oct 1, 2025
Could This Beaten-Down Stock Help You Become a Millionaire?. Key PointsCRISPR Therapeutics has a couple of pipeline candidates with massive opportunities.
Tue Sep 30, 2025
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Heres Why. In the latest trading session CRISPR Therapeutics AG (CRSP) closed at $61.67 marking a 2.24% move from the previous day.
Fri Sep 26, 2025
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy. CAMBRIDGE Mass. Sept. 25 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics Inc. (NASDAQ:NTLA) a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies today announced longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex
Thu Sep 25, 2025
Notable Friday Option Activity: CRSP CALM ABNB. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in CRISPR Therapeutics AG (Symbol: CRSP) where a total of 10666 contracts have traded so far representing approximately 1.1 million underlying shares. That amounts to ab
Fri Sep 19, 2025
JP Morgan Initiates Coverage of CRISPR Therapeutics (CRSP) with Overweight Recommendation. Fintel reports that on September 18 2025 JP Morgan initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Overweight recommendation.
Thu Sep 18, 2025
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects.
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRSP Stock trends
CRSP Stock performance
CRSP Stock analysis
CRSP investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings